EUVIMEDEUVIMED entdecken
Crossref

Embryo‐fetal safety evaluation of ondansetron in rats

Ana Carolina Casali Reis, Bárbara Campos Jorge, Suyane da Silva Moreira, Júlia Stein, Carolina Barizan Perdão, Beatriz de Matos Manoel, Arielle Cristina Arena iD

Birth Defects Research · 2023

DOI: 10.1002/bdr2.2154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Birth Defects Research, 2023. Verfasst von Ana Carolina Casali Reis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista - UNESP, Botucatu, São Paulo, B…. Hauptthemen laut MEDLINE: Antiemetics, Embryo, Mammalian, Ondansetron. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery. Since nausea and vomiting are common experiences during the first trimester of pregnancy, this antiemetic has been the main drug used during this period.

Methods

To evaluate the effects of ondansetron on the embryo‐fetal development, which are still very contradictory, pregnant rats were exposed to therapeutic doses of ondansetron (1.7 or 2.5 mg/kg) daily, from gestational day (GD) 6 to 15.

Results

No clinical signs of toxicity were observed in dams during the treatment. Although the hemato‐biochemical parameters were similar among the groups, histological changes, as well as a reduction in the weight of kidney were found in the treated dams. After fetal examination, no visceral and skeletal abnormalities were observed in treated fetuses.

Conclusion

In conclusion, therapeutic doses of ondansetron have low teratogenic potential in rats. These data provide important information about the drug safety during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsEmbryo, MammalianOndansetronAnimalsFemalePregnancyRatsNauseaVomiting

Stichwörter der Autor:innen

kidneynausea and vomitingorganogenesisratssafetyteratogenicity

Substanzen

AntiemeticsOndansetron

Autor:innen und Institutionen

  • Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista - UNESP, Botucatu, São Paulo, Brazil.
  • College of Health Science, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.
  • Center of Toxicological Assistance (CEATOX), Institute of Biosciences of Botucatu, Universidade Estadual Paulista - Botucatu (UNESP), Botucatu, São Paulo, Brazil.

ORCID-Profile: Arielle Cristina Arena

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Reis, A. C. C., Jorge, B. C., da Silva Moreira, S., Stein, J., Perdão, C. B., de Matos Manoel, B., & Arena, A. C. (2023). Embryo‐fetal safety evaluation of ondansetron in rats. Birth Defects Research. https://doi.org/10.1002/bdr2.2154

Vancouver

Reis ACC, Jorge BC, da Silva Moreira S, Stein J, Perdão CB, de Matos Manoel B, et al. Embryo‐fetal safety evaluation of ondansetron in rats. Birth Defects Research. 2023. doi:10.1002/bdr2.2154

BibTeX
@article{Reis2023,
  author = {Reis, Ana Carolina Casali and Jorge, Bárbara Campos and da Silva Moreira, Suyane and Stein, Júlia and Perdão, Carolina Barizan and de Matos Manoel, Beatriz and Arena, Arielle Cristina},
  title = {Embryo‐fetal safety evaluation of ondansetron in rats},
  journal = {Birth Defects Research},
  year = {2023},
  doi = {10.1002/bdr2.2154}
}
Kostenlos starten →